Literature DB >> 3948454

Age-associated changes in ceftriaxone pharmacokinetics.

W L Hayton, K Stoeckel.   

Abstract

Ceftriaxone pharmacokinetic parameters were compiled from recent publications. The subjects (27 female, 93 male) were from 1 day to 92 years old and appeared to have normal renal and hepatic function. In 1- to 8-day-old neonates, the half-life averaged 19 hours; it declined to 6.3 hours in 1- to 6-year-old subjects and then increased gradually throughout the remainder of the life-span to 14 hours in 75- to 92-year-old subjects. The age-associated changes in half-life appeared to result from changes in systemic clearance. The fraction of the dose eliminated renally averaged 70% in neonates and declined throughout childhood to 40 to 60% in adults, in whom it was age invariant. No clinically significant differences between males and females were detected in ceftriaxone kinetic parameter values. Plasma protein binding of ceftriaxone (100 mg/L) was about 70% in neonates and it increased throughout childhood to the adult value of 90 to 95%. To achieve a given free concentration of ceftriaxone, the same dosage per unit surface area can be used for children and adults, provided glomerular filtration and biliary secretion function are normal for age. Dosage should be reduced by as much as a factor of 5 in neonates less than 1 week of age and perhaps by a factor of 2 in the very old.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3948454     DOI: 10.2165/00003088-198611010-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  24 in total

1.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

2.  Age and ceftriaxone kinetics.

Authors:  J R Luderer; I H Patel; J Durkin; D W Schneck
Journal:  Clin Pharmacol Ther       Date:  1984-01       Impact factor: 6.875

3.  Multiple intravenous dose pharmacokinetics of ceftriaxone in man.

Authors:  I H Patel; K Miller; R Weinfeld; J Spicehandler
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

4.  Should clearance be normalised to body surface or to lean body mass?

Authors:  T H Hallynck; H H Soep; J A Thomis; J Boelaert; R Daneels; L Dettli
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

5.  Alterations in drug distribution and clearance due to obesity.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; J S Harmatz; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1981-06       Impact factor: 4.030

Review 6.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

7.  Pharmacokinetics of ceftriaxone in neonates and infants with meningitis.

Authors:  E Martin; J R Koup; U Paravicini; K Stoeckel
Journal:  J Pediatr       Date:  1984-09       Impact factor: 4.406

8.  A simple estimate of glomerular filtration rate in full-term infants during the first year of life.

Authors:  G J Schwartz; L G Feld; D J Langford
Journal:  J Pediatr       Date:  1984-06       Impact factor: 4.406

9.  Single-dose pharmacokinetics of ceftriaxone in infants and young children.

Authors:  U B Schaad; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

10.  Effect of age, gender, and obesity on midazolam kinetics.

Authors:  D J Greenblatt; D R Abernethy; A Locniskar; J S Harmatz; R A Limjuco; R I Shader
Journal:  Anesthesiology       Date:  1984-07       Impact factor: 7.892

View more
  25 in total

1.  Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients.

Authors:  Nicolas Simon; Bertrand Dussol; Emmanuelle Sampol; Raj Purgus; Philippe Brunet; Bruno Lacarelle; Yvon Berland; Bernard Bruguerolle; Saïk Urien
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Pharmacological properties of cephalosporins.

Authors:  W Christ
Journal:  Infection       Date:  1991       Impact factor: 3.553

3.  Ceftriaxone in the treatment of meningitis, gonococcal infections and other serious bacterial infections. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1990-03-01       Impact factor: 8.262

4.  The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites.

Authors:  L Hary; M Andrejak; S Leleu; J Orfila; J P Capron
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Crossover assessment of serum bactericidal activity and pharmacokinetics of five broad-spectrum cephalosporins in the elderly.

Authors:  R G Deeter; M P Weinstein; K A Swanson; J S Gross; L C Bailey
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Changes in trimethoprim pharmacokinetics after the newborn period.

Authors:  K Hoppu
Journal:  Arch Dis Child       Date:  1989-03       Impact factor: 3.791

Review 7.  Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.

Authors:  T R Perry; J J Schentag
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Influence of maturation and growth on cefetamet pivoxil pharmacokinetics: rational dosing for infants.

Authors:  W L Hayton; J Kneer; R de Groot; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo study.

Authors:  E Martin; S Fanconi; P Kälin; C Zwingelstein; C Crevoisier; W Ruch; R Brodersen
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

10.  Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy.

Authors:  W L Hayton; R Schandlik; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.